Issuer: ACES Awards

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 26 October 2026 - The Philippines shone on the opening day of the ACES Awards 2026, celebrating leaders and organisations whose achievements brought this year's theme, "Beyond Business," to life.

Honourees from across Asia come together on Day 1 of the ACES Awards 2026 in Kuala Lumpur, celebrating leadership, corporate excellence and sustainability under the theme "Beyond Business."

From empowering farmers to widening educational opportunities, these honourees showed how excellence becomes meaningful when it strengthens communities and creates possibilities for others.

"Our Philippine winners remind us that leadership carries its greatest meaning when it improves lives," said Dr Shanggari Balakrishnan, MORS Group CEO and ACES Awards President. "Their stories reflect the ingenuity, compassion and determination shaping a more inclusive and sustainable Asia."

Carrascal Nickel Corporation received the Community Initiative Award, demonstrating how responsible mining can support education, healthcare and livelihoods. Its commitment places community wellbeing at the heart of industrial progress.

AGRIDOM earned the Green Innovation Award and ACES SME of the Year, connecting agricultural technology with rural opportunity. Through drones and practical skills development, it helps Filipino farmers embrace a more sustainable future.

Dr Caroline Marian Enriquez, University President of Our Lady of Fatima University, was recognised among Asia's Most Inspiring Executives. Her leadership combines educational innovation with a belief in learning as a pathway to better lives.

Professional Services, Inc. - The Medical City received the Community Initiative Award, championing compassionate healthcare that reaches beyond hospital walls to serve wider communities.

Cebu Landmasters, Inc., Shell Pilipinas Corporation and Northern Cement Corporation each earned the Sustainability Rising Star Award. Their recognition highlighted the responsibility shared by property developers, energy providers and manufacturers to build environmental care into business growth.

San Miguel Global Power received both the Green Initiative Award and Community Initiative Award, linking environmental stewardship with community support. Its dual recognition reinforced a message shared across the Philippine honourees: lasting progress is measured by the lives improved along the way.

Hashtag: #ACESAwards

The Asia Corporate Excellence & Sustainability (ACES) Awards is a regional platform recognising outstanding leaders, organisations and sustainability champions across Asia.

Organised by MORS Group, its 13th annual edition in 2026 received 1,238 nominations from 35 countries across 45 industries, celebrating responsible leadership, corporate excellence and lasting positive impact.

The issuer is solely responsible for the content of this announcement.

Issuer: FAWCAR

MILAN, ITALY - Media OutReach Newswire - 25 October 2026 - On October 20, 2026, FAWCAR held a new-model launch event in Milan, officially announcing its entry into the Italian market. Five SUV models were launched simultaneously, with official prices ranging from EUR26,998.00 to EUR38,998.00.

FAWCAR Chairman Liu Zhongchen; Yang Xiaofeng, FAWCAR Vice President and Chairman of FAWCAR International Co., Ltd.; local partners, media representatives and vehicle owners attended the event to witness this milestone moment.

Deepening Local Demand, Precisely Adapting Products

FAWCAR Chairman Liu Zhongchen said Italy is one of Europe's most promising core automotive markets, and FAWCAR highly values its uniqueness and potential. To meet diversified local mobility needs, FAWCAR introduced two product matrices-BESTUNE and JOYEE-with five SUVs covering ICE, BEV and PHEV.

The ICE lineup covers diverse needs: BESTUNE T77, compact and practical, suits urban commuting and daily family use; BESTUNE T90, with generous space, meets long-distance family trips and intercity travel; BESTUNE B70S, with sporty styling and robust power, targets young buyers who value handling and design.

The new-energy models offer varied urban and long-distance solutions: JOYEE S04, a battery-electric SUV for urban commuting, leverages restricted-zone access and low energy consumption to address urban mobility pain points; JOYEE S08, a plug-in hybrid SUV with long range and strong power, handles mountain terrain and serves all-scenario family journeys.

Building a Professional Sales and Service Network

Local strategic partner BENTU-CHINACAR aims to build a nationwide, robust and professional sales and service network. By 2026, it plans 70 sales outlets and 100 service outlets; by 2027, 110 and 160; and by 2028, 130 and 180. All dealers and franchised stores will provide after-sales support. A central warehouse plus a Prato auxiliary warehouse will ensure efficient parts supply, bridging the last mile of service and supporting long-term worry-free use.

FAW has developed over 70 years, with cumulative production and sales exceeding 65 million vehicles. This launch marks FAWCAR's official rooting in Italy. In the future, FAWCAR will work with local partners to continuously expand its sales and service network and empower every user with high-quality mobility solutions.

Hashtag: #FAWCAR #ITALY #SUVs

The issuer is solely responsible for the content of this announcement.

Andrew Murray joins as Senior Vice President to deepen Nasdaq's Financial Technology client partnerships across Asia-Pacific as the region enters a defining era of market evolution

Bob McCooey, Vice Chairman and Head of International Listings, relocates to Singapore to broaden access to global capital for the region's companies and investors

SINGAPORE, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the appointment of Andrew Murray as Senior Vice President, Financial Technology, Asia-Pacific, strengthening its senior presence in one of the world's most dynamic regions.

Based in Singapore, Murray will deepen Nasdaq's Financial Technology client partnerships and accelerate business growth across Asia-Pacific, supporting financial institutions as they deliver on their technology and transformation priorities.

His appointment follows the relocation to Singapore of Bob McCooey, Vice Chairman and Head of International Listings, a move that enhances Nasdaq's engagement with the region's companies and their access to global capital.

These developments position Nasdaq to help advance the region's technology and capital markets ambitions.

"Asia-Pacific is entering one of the most significant cycles of innovation and market evolution in decades, driven by AI, data and the move toward always-on, globally connected markets," said Valerie Bannert-Thurner, Executive Vice President and Chief Revenue Officer, Financial Technology at Nasdaq. "Andrew's strong track record of helping financial institutions solve complex technology challenges will be invaluable as our clients navigate this rapidly changing landscape. Alongside Bob and our teams across the region, we are committed to being a trusted, long-term partner to Asia-Pacific's market ecosystems."

Murray brings more than three decades of experience leading teams and building long-term client partnerships at financial technology companies serving treasury, trading, corporate banking and capital markets clients. Most recently, he served as a leader in International Banking and Payments at FIS, where he supported clients across the full banking and payments value chain. His career includes senior international leadership positions at FIS in Banking & Markets and Post-Trade Solutions, as well as previous experience at Calypso Technology (now part of Nasdaq), SunGard, Wall Street Systems and Deutsche Bank.

"Asia-Pacific's ambition is reshaping the global economy, and the region's companies and investors increasingly seek access to deep, global pools of capital to fuel that growth," said Bob McCooey, Vice Chairman and Head of International Listings at Nasdaq. "Strengthening our presence on the ground will allow us to work more closely with the region's companies, investors and market participants, and deepen our role as a long-term partner across Asia-Pacific. Together, we can bring the full breadth of Nasdaq to support the innovation and economic growth that define this region."

McCooey's relocation underscores Nasdaq's commitment to broadening access to capital and supporting the development of companies and economies across Asia-Pacific. With more than two decades at Nasdaq, McCooey has partnered with many of the region's most innovative companies on their journeys to the global capital markets. Being based in Singapore will facilitate closer collaboration with clients, partners and local market ecosystems.

Basing two additional senior leaders in Singapore also reflects Nasdaq's enduring commitment to Asia-Pacific. As the region's markets become more connected, continuous and technology-driven, Nasdaq will continue to partner with clients, exchanges and market ecosystems to strengthen the trusted infrastructure that supports capital formation and long-term economic growth.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world's economies. We architect the world's most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying the technology, data, and advanced analytics that enable our clients to capture opportunities, navigate risk, and strengthen resilience. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

Copyright 2026 GlobeNewswire, Inc.

Teknologi Cerdas. Definisi Baru Kemewahan

WUHU, Tiongkok, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Mengusung tema "INTELLIGENCE, ENLIGHTENED (KECERDASAN, TERCERAHKAN)," LUXEED sukses menggelar acara Peluncuran Merek Globalnya pada tanggal 21 Oktober 2026, di Shenshan Intelligent Valley, Wuhu, Provinsi Anhui, Tiongkok.

LLounge, MPV mewah unggulan berteknologi cerdas, dan Stormax, SUV unggulan berperforma tinggi, resmi debut di panggung global. Kedua model ini menampilkan dua ekspresi berbeda dari merek LUXEED. Acara itu memperkenalkan tujuan, visi, audiens target, serta strategi pertumbuhan global LUXEED.

Di tengah kemajuan era teknologi cerdas, ekspektasi terhadap kemewahan terus berkembang. Generasi baru konsumen produk mewah kini lebih mengutamakan pengalaman yang dipersonalisasi dan teknologi cerdas yang terintegrasi tanpa hambatan, bukan sekadar simbol status atau spesifikasi bahan yang digunakan.

LUXEED diciptakan sebagai respons terhadap perubahan ini dengan memadukan teknologi cerdas dan desain yang berpusat pada manusia. Perpaduan itu menghadirkan ekspresi baru kemewahan yang disesuaikan dengan ekspektasi generasi yang sedang muncul ini.

Merek LUXEED dibangun di atas tiga nilai utama: Kenikmatan Berkendara Maksimal, Kenikmatan yang Melampaui Kelasnya, dan Kecerdasan Teknologi Tingkat Tertinggi. Ketiganya memadukan dinamika berkendara yang menarik, ruang kabin mewah yang dirancang dengan cermat, serta teknologi cerdas yang berpusat pada manusia.

Filosofi merek LUXEED, "Kecerdasan Mendefinisikan Ulang Kemewahan & Kenikmatan Berkendara," menempatkan teknologi cerdas sebagai landasan untuk menghadirkan konsep baru dalam berkendara dan menikmati kenyamanan di setiap perjalanan.

LUXEED memperkenalkan misinya, "MENGHADIRKAN MOBILITAS IDAMAN MELALUI TEKNOLOGI BERKENDARA CERDAS TINGKAT TERTINGGI," serta visinya untuk menjadi pemimpin global dalam teknologi berkendara cerdas premium. Proposisi nilai LUXEED, "SAYA" MENGEMUDI, ANDA MENIKMATI diwujudkan melalui dua model unggulannya. LLounge mengutamakan kenyamanan penumpang, sedangkan Stormax berfokus pada performa berkendara dan kenikmatan berkendara dengan teknologi cerdas.

LUXEED berencana memasuki 18 pasar pada 2026?2027, berekspansi ke 36 pasar pada 2028?2029, dan menjangkau lebih dari 60 pasar paling lambat pada 2030. Uni Emirat Arab, Thailand, dan Indonesia termasuk di antara pasar awal yang menjadi target LUXEED.

LUXEED akan memadukan standar produk global yang konsisten dengan kapabilitas Litbang berskala global serta proses validasi yang disesuaikan dengan kondisi pasar setempat. Di samping itu, perusahaan akan membangun pengalaman pelanggan terintegrasi melalui berbagai titik interaksi online dan offline.

Dari keselarasan dengan perkembangan zaman, pengungkapan nilai-nilai merek, hingga cetak biru global, LUXEED telah merampungkan alur narasi mereknya secara utuh. INTELLIGENCE, ENLIGHTENED (KECERDASAN, TERCERAHKAN) ? tema peluncuran ini juga menjadi prinsip yang memandu merek LUXEED. Melalui teknologi cerdas, LUXEED akan membuka cakrawala baru dalam mobilitas mewah bagi pengguna di seluruh dunia.

Copyright 2026 GlobeNewswire, Inc.

BANGKOK, THAILAND - Media OutReach Newswire - 24 October 2026 - Agoda, an online travel platform that is part of Booking Holdings, has its largest office worldwide in Bangkok, with more than 4,500 staff - over half its global workforce.

The Bangkok team develops software algorithms, artificial intelligence, and data analytics that help drive the platform, which offers accommodations in more than 200 countries and territories.

Agoda has received investment promotion from the Thailand Board of Investment (BOI) for International Business Center activity. Agoda's Bangkok base underscores Thailand's potential to become a tech talent hub.

Mr. Narit Therdsteerasukdi, Secretary General of the BOI, visited the office at the One Bangkok complex and met Agoda Chief Executive Omri Morgenshtern and senior management. The Bangkok site serves as Agoda's Global Tech & Operations Hub, with systems developed in Thailand deployed across a platform that lists more than 6 million properties in 39 languages. The company employs more than 8,000 people in 25 markets.

More than half of the Bangkok staff are Thai, while about 2,000 foreign specialists come from more than 80 countries. Roles range from software engineering, data science and AI to product management, marketing and international business management.

"Thailand has a deep pool of skilled people in data analytics, IT and communications, engineering and business management, and an open work culture where people of many nationalities collaborate well," Mr. Narit said. "Combining Thai and foreign expertise allows the company to place complex, high value-added activities in Thailand while creating opportunities to transfer knowledge, upgrade skills, and build the country's tech ecosystem over the long term."

Agoda's foreign experts get help with visas and work permits in one place. The BOI, the Immigration Bureau, and the Department of Employment facilitate both through the Thailand Investment and Expat Service Center, a one-stop service at One Bangkok, where Agoda's office is also based. That helps experts from around the world join Thai teams quickly and conveniently. It suits a business that constantly trains, coordinates, and travels internationally.

Agoda also runs a talent pipeline with Thai universities. Its Tech Camp Day, held three times a year, brings in more than 100 students per session, and its internship program takes more than 500 students a year from over 10 universities. More than 20 percent of interns have gone on to join the company.

"Working at a global technology company gives Thai professionals exposure to the standards, tools, and working methods of international teams," Morgenshtern said. "That experience can be carried into new businesses, startups, and the upgrading of companies across industries, spreading knowledge and supporting Thailand's long-term economic growth."

"A global company like Agoda choosing Thailand as its main base for high-skilled technology work is an example of success in attracting investment driven by people and knowledge," Mr. Narit said. "These investments create high-value jobs and give Thais the chance to work with experts from around the world. The skills they gain today will help them build new businesses and develop the country in the years ahead."

Thailand Board of Investment (BOI)

Established in 1966, the Thailand Board of Investment (BOI) has spent six decades promoting high-value investment from both foreign and Thai investors, strengthening the country's competitiveness and driving its transition toward a sustainable, balanced new economy.

Investment Services Center - PR Section, Office of the Board of Investment (BOI)

555 Vibhavadi-Rangsit Road, Chatuchak, Bangkok 10900 Tel. +66 (0) 2553 8111, Fax +66 (0) 2553 8222

The issuer is solely responsible for the content of this announcement.

Hashtags: #Thailandboardofinvestment #BOI #FDI #Investment

https://www.boi.go.th/en/index/

GUANGZHOU, Tiongkok, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Tec-Do hari ini menyelenggarakan Technology Growth Conference 2026 (TGC 2026) di Guangzhou dengan mengusung tema "AI is Profitable (AI itu Menguntungkan)."

Dengan menghadirkan pelopor AI, Dr. Kevin Knight, serta para pembicara dari OpenAI, Google, Alibaba, ByteDance, dan Tencent, konferensi ini membahas bagaimana AI dapat memberikan nilai bisnis yang terukur.

Dalam acara tersebut, Tec-Do meluncurkan Navos Pro, yang menurut perusahaan merupakan Pro-Agent pertama di industri. Dikembangkan berdasarkan tiga karakteristik utama-Profesional, Proaktif, dan Menguntungkan-produk ini memperkuat pendekatan Tec-Do dalam menghadirkan AI for Work yang berorientasi pada hasil.

Dari Kemampuan AI hingga Hasil Bisnis

Dalam pidato utama pembukaannya yang bertajuk "From Language to Action: The Next Leap in AI (Dari Bahasa ke Tindakan: Lompatan Berikutnya dalam AI)" Dr. Knight memanfaatkan pengalamannya di dunia akademis dan industri untuk mengidentifikasi AI for Work sebagai salah satu arah utama penerapan AI.

Shuhao Li, Pendiri dan CEO Tec-Do, memaparkan peluang bisnis bernilai triliunan dolar di tiga bidang pengeluaran perusahaan, yaitu pemasaran dan penjualan, coding dan pengembangan produk, serta manajemen. Ketiga bidang tersebut berkaitan dengan AI for Growth, AI for Innovation, dan AI for Administration. Dalam kerangka ini, Li memosisikan Navos Pro sebagai salah satu pesaing utama di bidang AI for Growth.

"Kami berfokus sepenuhnya pada AI for Work yang berorientasi pada hasil," ujar Li.

Dirancang untuk mendukung e-commerce lintas negara, perdagangan internasional, pemasaran, dan analisis bisnis, Navos Pro menggabungkan:

Profesional: Membangun pusat informasi privat dari situs web suatu merek dan menyimpan konteks bisnis untuk menghasilkan output yang selaras dengan tujuan komersial merek tersebut.

Proaktif: Memantau data sepanjang waktu untuk mengidentifikasi peluang dan merekomendasikan tindakan, sedangkan wewenang pengambilan keputusan tetap berada di tangan manusia.

Menguntungkan: Menghubungkan strategi, pengembangan materi iklan, dan eksekusi periklanan dengan hasil yang terukur, termasuk nilai transaksi bruto (GMV) dan tingkat pengembalian investasi (ROI).

Kemampuan ini didukung oleh model khusus dengan 32 miliar, 27 miliar, dan 5 miliar parameter, pengetahuan industri, lebih dari 70 integrasi MCP, serta lebih dari 100 keterampilan. Menurut Tec-Do, platform ini memantau lebih dari 1 miliar titik data setiap hari. Learning Loop menghubungkan hasil dengan pengoptimalan strategi, sedangkan Navos RSI menggunakan pembelajaran penguatan berbasis agen untuk meningkatkan kualitas Agent Harness miliknya.

Arsitektur ini mendukung penerapan di berbagai pasar, saluran, dan industri. Portofolio produk ini terdiri dari Navos Lite dan Navos Pro, yang mencakup alur kerja pemasaran internasional yang menyeluruh.

Dari Merespons hingga Menginisiasi Pekerjaan

Li menggambarkan evolusi dari Chatbot ke Copilot hingga Pro-Agent sebagai pergeseran dalam hal siapa yang mengambil inisiatif untuk memulai pekerjaan: dari merespons permintaan, membantu eksekusi, hingga secara proaktif mengidentifikasi peluang dan mendorong pertumbuhan. Li berpendapat bahwa industri AI tengah beralih dari sekadar menyediakan kemampuan menuju pembuktian nilai bisnis yang dihasilkan.

Dengan memanfaatkan pengalamannya dalam melayani ratusan ribu merek yang berekspansi ke pasar internasional, Tec-Do memperluas pendekatan ini melalui kemitraan. Menurut perusahaan, Tec-Do menjadi salah satu mitra teknologi global pertama untuk ChatGPT Ads pada Juli 2026. Kemitraan ini membantu berbagai merek meningkatkan ROI hingga 2,5 kali lipat dari tingkat sebelumnya. Pada bulan Agustus, Tec-Do bermitra dengan Tencent WorkBuddy untuk menerapkan kemampuan AI dalam periklanan internasional.

Li menyatakan bahwa AI for Growth merupakan langkah awal, dengan rencana untuk memperluas kemampuan Tec-Do ke AI for Innovation dan AI for Administration.

Mendorong Komersialisasi AI

Lorry Destainville, Kemitraan Monetisasi di OpenAI berbagi pandangannya mengenai komersialisasi ChatGPT. Ia menyatakan bahwa ChatGPT menjangkau 1,2 miliar pengguna setiap minggu dan OpenAI tengah mengeksplorasi pengembangan Sponsored Agents dan Visual Ads. Ia juga berterima kasih kepada Tec-Do atas kolaborasinya dalam mengembangkan berbagai alat AI yang praktis dan terukur untuk mendukung pertumbuhan berbagai merek.

Tiga sesi diskusi panel, yang dimoderasi oleh Maeve Zhang, Wakil Presiden Pemerekan dan Hubungan Masyarakat di Tec-Do, membahas dampak AI terhadap bisnis, ekspansi internasional, dan kolaborasi ekosistem, dengan menghadirkan penyedia teknologi, pengusaha, dan investor.

Konferensi ini ditutup dengan pengumuman Pro-Agent Global Challenge oleh Eileen Nie, Mitra Pendiri dan Kepala Inkubasi Ekosistem dan Investasi Strategis di Tec-Do. Inisiatif ini mengundang para pengusaha dari seluruh dunia untuk mengajukan proyek di bidang arsitektur agen, pemasaran berbasis AI, gateway konten AI, dan infrastruktur komputasi. Inisiatif ini juga menawarkan akses ke modal, sumber daya industri, serta saluran pertumbuhan global.

Tentang Tec-Do

Didirikan pada tahun 2017, Tec-Do merupakan perusahaan pemasaran AI terkemuka yang menyediakan solusi pemasaran berorientasi pada hasil untuk mendukung pertumbuhan bisnis global. Perusahaan ini didukung oleh model bahasa besar multimodal (MLLM) Tec-Chi dan platform pemasaran multiagen Navos.

Melalui rangkaian produk berbasis AI yang berorientasi pada kinerja, Tec-Do menyediakan solusi pemasaran yang menyeluruh. Produk-produk ini merestrukturisasi dan mengotomatiskan proses pemasaran yang sangat penting bagi operasional bisnis, termasuk intelijen pasar, pembuatan konten, pelaksanaan kampanye, dan pengoptimalan kinerja di berbagai saluran media global. Pada tahun 2025, Tec-Do melayani lebih dari 100.000 pengiklan dengan basis pelanggan yang beragam, mencakup sektor e-commerce, gaming, hiburan, dan perdagangan lokal.

Copyright 2026 GlobeNewswire, Inc.

Klien EBC Financial Group kini dapat melakukan trading melalui aplikasi yang sama yang mereka gunakan untuk membuka, mendanai, dan mengelola akun

LONDON, Oct. 24, 2026 (GLOBE NEWSWIRE) -- EBC Financial Group (EBC) telah memperluas layanan trading langsung di EBC App dengan menghadirkan pengelolaan akun, fitur pendanaan, dan eksekusi trading dalam satu platform seluler.

Fitur trading yang pertama kali diperkenalkan secara bertahap pada tanggal 14 September 2026 ini lalu diperluas ke sejumlah pas ar lainnya, dengan peluncuran lanjutan pada tanggal 21 Oktober. Akses ke layanan ini tetap bergantung pada lokasi setiap klien, kelayakan akun, serta entitas EBC yang menyediakan layanan tersebut.

"Misi kami adalah membantu klien melakukan trading dengan lebih baik dengan membuat platform kami dapat diakses kapan saja dan di mana saja. EBC App kini memungkinkan klien untuk memantau akun, melacak status order, dan mengelola eksposur risiko mereka tanpa perlu berpindah-pindah platform. "Integrasi berbagai fungsi ini akan membantu menyederhanakan pengelolaan akun sehari-hari, sekaligus memastikan risiko dan tanggung jawab dalam trading tetap dipahami dengan jelas," ujar Andria Phiniefs, Direktur Pemasaran EBC Financial Group.

Fitur yang Dapat Digunakan Klien di Aplikasi

Klien dapat melihat kuotasi harga secara real time dan melakukan trading Kontrak untuk Selisih (CFD), yang memungkinkan mereka mengambil posisi berdasarkan pergerakan harga tanpa harus memiliki aset acuan. Tersedia lebih dari 300 instrumen CFD untuk trading, termasuk pasangan valas, komoditas, indeks, saham, dan reksa dana yang diperdagangkan di bursa (ETF). Klien dapat memasang market order yang langsung dieksekusi pada harga pasar saat itu, atau pending order yang baru akan dieksekusi ketika harga mencapai level yang telah mereka tentukan. Klien juga dapat mengatur level take-profit dan stop-loss agar posisi tertutup secara otomatis saat keuntungan atau kerugian mencapai batas yang telah ditentukan, membatalkan order, serta menutup beberapa posisi sekaligus dengan sekali ketuk.

Fitur-fitur ini memungkinkan trader menetapkan batas sebelum terjadi pergerakan harga, mengingat trading CFD dilakukan dengan menggunakan margin. Leverage dapat memperbesar keuntungan sekaligus kerugian, dengan potensi kerugian yang bahkan dapat melebihi jumlah deposit. Penggunaan stop-loss juga tidak menjamin kerugian dapat dibatasi sepenuhnya. Saat pasar bergerak dengan cepat, harga dapat melompati level yang telah ditentukan, fenomena yang dikenal sebagai gap. Akibatnya, order mungkin dieksekusi pada harga yang kurang menguntungkan. Fitur-fitur order yang telah dijelaskan saat EBC meluncurkan aplikasinya pada bulan Juli lalu bertujuan memberikan kendali yang lebih baik kepada trader atas eksposur risiko mereka, bukan menghilangkan risiko tersebut.

Satu Aplikasi untuk Membuka Akun hingga Melakukan Trading

EBC mengumumkan kehadiran EBC App pada tanggal 7 Juli 2026 sebagai platform pengelolaan akun. Sebelumnya, klien telah dapat membuka akun dan menyelesaikan proses verifikasi identitas melalui aplikasi, melakukan penyetoran dan penarikan dana, serta mengakses layanan dukungan pelanggan dalam berbagai bahasa yang tersedia selama 24 jam 7 hari seminggu. Klien juga dapat berpindah-pindah akun, dengan informasi dana, posisi, dan aktivitas trading yang tersinkronisasi secara real time. Dengan penambahan fitur trading langsung, aplikasi yang sama kini juga mencakup tahap terakhir dalam proses trading, yaitu pemasangan order.

Apa yang Terjadi Setelah Mengetuk Layar

Melalui Smart Order Routing Engine milik EBC Financial Group, lebih dari 87,6% order EBC dieksekusi pada harga yang lebih baik dibandingkan harga yang diminta. Dengan kata lain, order tersebut dieksekusi pada harga yang lebih menguntungkan bagi klien dibandingkan harga yang ditawarkan saat order dipasang. Infrastruktur trading EBC menawarkan kecepatan eksekusi rata-rata 20 milidetik, kemampuan memproses hingga 1.000 order per detik, dan tingkat stabilitas sistem sebesar 98,75%. Infrastruktur ini didukung oleh server dengan jalur jaringan khusus privat Tier 4 yang tersebar di lima pusat keuangan global serta 30 pusat data di seluruh dunia.

Harga ditentukan berdasarkan informasi dari lebih dari 50 penyedia likuiditas, baik bank maupun nonbank, termasuk J.P. Morgan, UBS, Barclays, dan Goldman Sachs. EBC menawarkan spread raw ECN mulai dari 0,0 pip, yaitu selisih antara harga beli dan harga jual, serta kedalaman pasar lima tingkat yang menunjukkan harga dan volume yang tersedia di luar kuotasi harga terbaik.

Ketersediaan EBC App

EBC App yang disediakan oleh EBC Financial Group (SVG) LLC dapat diunduh untuk perangkat iOS dan Android melalui halaman unduhan resmi di https://www.ebc.com/mobile. Ketersediaan fitur trading, instrumen, dan layanan akun bergantung pada persyaratan setempat yang berlaku serta kelayakan klien.

Trading valas dan CFD menggunakan margin memiliki risiko yang signifikan, termasuk potensi mengalami kerugian dalam waktu singkat. Instruksi stop-loss dapat membantu mengelola eksposur risiko, tetapi tidak menjamin bahwa order akan dieksekusi pada harga tertentu. Perlindungan yang tersedia bagi klien, termasuk pembatasan kerugian, bergantung pada entitas EBC yang menjalin kontrak dengan mereka, klasifikasi akun, serta aturan yang berlaku.

Untuk informasi lebih lanjut mengenai EBC, kunjungi: www.ebc.com.

Penafian: Materi ini hanya untuk tujuan informasi dan bukan merupakan rekomendasi atau saran dari EBC Financial Group dan seluruh entitasnya ("EBC"). Trading Valas dan Kontrak untuk Selisih (Contracts for Difference, CFD) pada margin memiliki tingkat risiko yang tinggi dan mungkin tidak cocok untuk semua investor. Kerugian dapat melebihi nilai deposit Anda. Sebelum melakukan trading, Anda sebaiknya mempertimbangkan dengan cermat tujuan trading, tingkat pengalaman, serta toleransi risiko Anda. Konsultasikan dengan penasihat keuangan independen bila diperlukan. Data statistik atau performa investasi di masa lalu tidak menjamin performa pada masa mendatang. EBC tidak bertanggung jawab atas segala kerugian yang timbul akibat mengandalkan informasi ini.

Tentang EBC Financial Group

Didirikan di London, EBC Financial Group telah meraih penghargaan "Broker Global Terbaik" dari World Finance selama empat tahun berturut-turut. EBC Financial Group mengoperasikan sejumlah entitas yang diatur oleh FCA, ASIC, CIMA, dan FSCA, serta melayani lebih dari 8 juta pengguna terdaftar di lebih dari 100 negara dan wilayah. Sebagai Mitra Resmi FC Barcelona, EBC juga aktif mendukung edukasi keuangan melalui kerja sama dengan Departemen Ekonomi Universitas Oxford, program United to Beat Malaria dari UN Foundation, serta berbagai organisasi amal anak di seluruh dunia melalui yayasan amalnya, EBC Group Foundation.

Copyright 2026 GlobeNewswire, Inc.

*In partnership with the Foreign Ministry, the Ministry of Transport, Communications and Information Technology, and Oman Investment Authority, Asyad Group is organizing the forum to build on Oman's role in international dialogue on the future of the maritime industry.

*Omani and international leaders with operational and commercial expertise will discuss practical solutions to strengthen the resilience of maritime networks and flow of global trade.

*Muscat Maritime Resilience Framework: participants will consider planned mechanisms to strengthen maritime networks and deepen international cooperation to protect the flow of global trade.

MUSCAT, Oman, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Asyad Group will host the Muscat Maritime Resilience Forum 2026 on 27?28 October in partnership with the Foreign Ministry of Oman, the Ministry of Transport, Communications and Information Technology, and Oman Investment Authority. The partnership reflects a coordinated national effort to strengthen Oman's role in international discussions on the future of trade and global maritime routes.

The forum will bring together senior executives, academics and maritime experts from major companies and international institutions in one platform dedicated for professional dialogue and the exchange of hands-on experience. Participants will examine the shared challenges facing the global maritime system and explore practical solutions that make its networks more resilient and better connected in support of international trade.

The forum will examine how resilient, interconnected maritime networks support supply chains, businesses, markets and economies. Building that resilience requires operational know-how and cooperation across every part of the sector: shipping, ports, logistics, technology, insurance and the markets tied to global trade. Private sector leaders will steer the sessions, drawing on real operational and commercial challenges to identify practical approaches that translate shared experience into clear next steps.

Eng. Abdulrahman Al Hatmi, Group Chief Executive Officer of Asyad Group, said:

"Global trade is only as resilient as the maritime networks that sustain it. Those networks must keep markets connected while adapting to the disruptions and evolving conditions that shape the movement of goods and the continuity of supply chains. That is why we are bringing leading industry minds and experts to Muscat to work through common challenges and help shape a maritime system that is stronger and better prepared for the future. As host, we bring Asyad Group's commercial and operational expertise to this dialogue, as we believe maritime resilience is a shared responsibility that requires ongoing cooperation across the industry."

Hosting the forum reflects Oman's approach to economic diplomacy, which uses international relationships built on trust to create platforms that bring decision-makers and experts together on priority issues for the global economy. Through the forum, Muscat emerges as a trusted international meeting point for maritime leaders from around the world. Together, they will address a shared challenge that extends beyond any one market and can only be met through coordinated action. Oman's strategic location on maritime trade routes reinforces this role, along with its ports, infrastructure, maritime services and logistics solutions, which connect regional and global markets and widen trade options.

The Muscat Maritime Resilience Forum marks a significant step in positioning Muscat as an international hub for business and professional dialogue in the maritime sector. It will foster closer cooperation and knowledge exchange among maritime and logistics leaders across markets, supporting collective efforts to strengthen the resilience of the networks that sustain global trade. Insights and recommendations from the forum will inform the development of the Muscat Maritime Resilience Framework.

Copyright 2026 GlobeNewswire, Inc.

Intelligent Technology. A New Definition of Luxury

WUHU, China, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Themed "INTELLIGENCE, ENLIGHTENED," LUXEED successfully held its Global Brand Launch on October 21 at Shenshan Intelligent Valley, Wuhu, Anhui, China.

The LLounge intelligent luxury flagship MPV and Stormax performance flagship SUV made their global debuts, showcasing two distinct expressions of the brand. The event introduced LUXEED's purpose, vision, target audience and global growth strategy.

As the intelligent era unfolds, expectations of luxury are evolving. A new generation of luxury consumers places greater emphasis on personalized experiences and seamless intelligence, rather than status symbols or material specifications alone. LUXEED was created in response to this shift, bringing intelligent technology and human-centered design together to deliver a new expression of luxury tailored to the expectations of this emerging generation.

LUXEED's brand is built around three core values: Extreme Driving Pleasure, Beyond-Class Enjoyment, and Ultimate Intelligence. Together, they unite engaging driving dynamics, thoughtfully designed luxury spaces and human-centered intelligent technology.

The brand philosophy, "Intelligence Redefines Luxury & Driving Pleasure," positions intelligence as the foundation for reimagining both driving and the comfort of every journey.

LUXEED unveiled its mission, "THROUGH ULTIMATE INTELLIGENT DRIVING, UNVEIL ASPIRATIONAL MOBILITY," and its vision to become the global leader in premium intelligent driving. Its value proposition, "I" DRIVE, YOU ENJOY, comes to life through two flagship models: LLounge prioritizes passenger comfort, while Stormax focuses on driving performance and intelligent driving pleasure.

LUXEED plans to enter 18 markets in 2026?2027, expand to 36 markets by 2028?2029, and reach more than 60 markets by 2030. The UAE, Thailand and Indonesia are among its initial target markets.

The brand will combine consistent global product standards with global R&D capabilities and localized validation, while building an integrated customer experience across online and offline touchpoints.

From resonance with the times, to the expression of value, to a global blueprint, LUXEED has completed a full brand narrative arc. INTELLIGENCE, ENLIGHTENED - the theme of the launch is also the brand's guiding creed: through intelligent technology, LUXEED will enlighten a new frontier of luxury mobility for users around the world.

Copyright 2026 GlobeNewswire, Inc.

*ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha (FRα) expression levels

*Confirmed objective response rates (cORR) of 64.5% at the 6.4 mg/kg dose in patients with high-grade serous platinum-resistant ovarian cancer

*Median duration of response not yet reached at either dose level at median 7 months follow-up, with six-month progression-free survival rate of 61% in both groups

*Favorable tolerability profile, particularly at 6.4 mg/kg, supports continued clinical development in partnership or through a strategic collaboration

*Conference call with Zymeworks management on October 27 at 8:30 am Eastern Time (ET)

VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the randomized dose-optimization portion of its ongoing Phase 1 study evaluating ZW191, a FRα-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

The presentation highlights compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer (PROC), including patients with high-grade serous disease across all levels of FRα expression. The results demonstrate compelling response rates, durability and a favorable tolerability profile, particularly at the 6.4 mg/kg dose, further supporting the potential of ZW191 to address limitations of currently available FRα-targeted therapies and expand treatment opportunities for patients with ovarian cancer.

"We are highly encouraged by these results, which further demonstrate the differentiated clinical profile of ZW191 and its potential to deliver meaningful benefit to patients with platinum-resistant ovarian cancer," said Sabeen Mekan, M.D., Senior Vice President and Chief Medical Officer, Zymeworks. "The robust response rates observed at both doses, including meaningful activity in patients with low or negative FRα expression, reinforce the potential of ZW191 to benefit a broader patient population. Importantly, the encouraging durability of responses and favorable tolerability profile, particularly at 6.4 mg/kg, provide valuable insights to guide dose selection and the next stage of clinical development."

The analysis included efficacy and safety data from 80 patients with PROC randomized to receive ZW191 at 6.4 mg/kg (n=37) or 9.6 mg/kg (n=43) every three weeks, as of the September 10, 2026 data cutoff date. Patients were heavily pretreated, having received a median of four prior lines of therapy, with 45% receiving five or more prior lines. Median follow-up was seven months. FRα expression was assessed by immunohistochemistry and categorized as low/negative (0%-24%), intermediate (25%-74%) or high (75%-100%) based on the percentage of tumor cells with 2+ or 3+ staining intensity.

Key Findings

Among response-evaluable patients with high-grade serous PROC, ZW191 demonstrated a cORR of 64.5% at 6.4 mg/kg and 55.3% at 9.6 mg/kg, with disease control rates of 100% and 92.1%, respectively. These findings demonstrate compelling anti-tumor activity at both doses in a heavily pretreated patient population.

ZW191 demonstrated meaningful anti-tumor activity across FRα expression in patients with high-grade serous PROC. Confirmed objective response rates were 69.2% in patients with high FRα expression, 50.0% in patients with intermediate FRα expression and 55.0% in patients with low or negative FRα expression. These findings support the potential of ZW191 to show improved efficacy than existing FRα targeted therapies in FRα high population and meaningfully benefit patients with lower expression who may not be eligible for currently approved FRα targeting therapies.

Responses to ZW191 were deep and durable, with median duration of response not yet reached at either dose. Six-month progression-free survival (PFS) was 61% in both groups, while median PFS was 7.9 months at 6.4 mg/kg and 9.8 months at 9.6 mg/kg in patients with high-grade serous PROC. At the time of data cutoff, 45% of patients remained on treatment, and PFS data continue to mature, especially at 6.4 mg/kg.

ZW191 continued to demonstrate a favorable tolerability profile, particularly at 6.4 mg/kg. Grade 3 or higher treatment-related adverse events occurred in 22% of patients receiving 6.4 mg/kg compared with 44% at 9.6 mg/kg. Treatment-emergent adverse events leading to dose reductions occurred in 5% and 33% of patients, respectively, while discontinuations due to adverse events occurred in 14% and 19%. No deaths due to treatment-emergent adverse events were reported in either treatment group. The overall safety profile was manageable and supports continued clinical development.

"These results are particularly promising for patients with platinum-resistant ovarian cancer who have exhausted available treatment options," said Jung-Yun Lee, M.D., Ph.D., Yonsei Cancer Center and Severance Hospital, Seoul, Republic of South Korea, and primary investigator who presented the results at ESMO 2026. "We observed substantial anti-tumor activity in patients who had received multiple prior therapies, including meaningful responses across high, intermediate and low or negative FRα expression levels. The encouraging durability of responses, together with the favorable safety profile observed at the lower dose, suggests ZW191 has the potential to become an important new treatment option for patients with this difficult-to-treat disease."

The findings demonstrate encouraging anti-tumor activity across the 6.4 mg/kg and 9.6 mg/kg dose levels, with a more favorable tolerability profile at 6.4 mg/kg. These results will inform optimal dose selection for further clinical development.

ZW191's differentiated profile, including its novel FRα-targeting antibody, proprietary topoisomerase I inhibitor payload, ZD06519, and high drug-to-antibody ratio, supports its potential to address key limitations of existing therapies and broaden the applicability of FRα-targeted treatment approaches.

Investor Call Details

Zymeworks invites investors and the general public to view and listen to a live webcast of its conference call with investment analysts at 8:30 am ET on October 27, 2026.

Dial-in details and webcast link are available on Zymeworks' website at https://ir.zymeworks.com/events-and-presentations. A webcast replay of the call will be available on the Zymeworks website within 24 hours following the conclusion of the live call and will be archived for a limited period.

About ZW191

ZW191 is an antibody-drug conjugate engineered to target a protein called folate receptor-⍺ found in ~75% of high-grade serous ovarian carcinomas,1 over 50% of endometrial cancers,2,3 and ~70% of lung adenocarcinomas4. ZW191's differentiated design strongly supports its ability to internalize into FR⍺-expressing cells with the potential to release bystander active topoisomerase-1 inhibitor (ZD06519), a novel proprietary payload developed by Zymeworks to kill tumor cells.

The Company has engaged MTS Healthcare to evaluate strategic partnering opportunities to fund further development for ZW191 with the objective of maximizing long-term value.

About Zymeworks Inc.

Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. The Company's asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI? (revefenacin), with a differentiated internal research and development engine. Zymeworks' portfolio also includes Ziihera? (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks' proprietary antibody engineering technologies.

Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric? platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks' integrated drug development expertise, enable the Company to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships.

For more information about Zymeworks, its portfolio and pipeline, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Forward-looking statements in this press release include, but are not limited to, statements that relate to the potential safety profile and therapeutic effects of ZW191; Zymeworks' development of product candidates; status of studies and the related data; anticipated clinical data presentations; Zymeworks' implementation of its long-term strategy; and other information that is not historical information. When used herein, words such as "plan", "believe", "expect", "may", "continue", "anticipate", "potential", "will", "on track", "progress", "preserve", "intend", "could", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks' current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.

Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks' or its partners' product candidates, including ZW191, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments or royalties under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of global and regional geopolitical or public health developments on Zymeworks' business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks' behalf; zanidatamab may not be successfully commercialized; Zymeworks' business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks' evolution of its business strategy may not deliver meaningful shareholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates, including ZW191; Zymeworks' assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under "Risk Factors" in Zymeworks' quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

---

1 Kobel, M., Madore, J., Ramus, S. et al., Br J Cancer 111, 2297?2307 (2014).

2 May B, Conway N, Truong T, Linhart S, et al. FRα, B7-H4, & HER2 Expression in Endometrial Cancer: Assessing the Promise of Antibody Drug Conjugate Therapies. Presented at: SGO 2025 Winter Meeting; January 30 - February 1, 2025; Whistler, British Columbia, Canada.

3 Senol S, Ceyran AB, Aydin A, Zemheri E, Ozkanli S, K?semetin D, Sehitoglu I, Akalin I. Folate receptor α expression and significance in endometrioid endometrium carcinoma and endometrial hyperplasia. Int J Clin Exp Pathol. 2015 May 1;8(5):5633-41.

4 O'Shannessy DJ, et al., Oncotarget. 2012 Apr; 3(4):414-25.

Copyright 2026 GlobeNewswire, Inc.

BANGKOK, THAILAND - Media OutReach Newswire - 24 October 2026 - Makers of the capacitors, magnets and battery materials inside AI servers and electric vehicles (EVs) are lining up to invest in Thailand.

Since 2023, they have filed 35 advanced materials projects worth about $690 million (23.5 billion baht) with the Thailand Board of Investment (BOI), the government's investment promotion agency. Surging demand for AI, EVs, and clean energy is pushing global suppliers to build upstream capacity in the country.

The projects, filed through the first half of 2026, cover multilayer ceramic capacitors (MLCCs), thermal graphite films, high-performance ceramics, battery and fuel-cell materials, neodymium magnets, glass and quartz fabrics for printed circuit boards, and nanomaterials for precision manufacturing. Together they mark a shift for one of Southeast Asia's largest economies from downstream assembly toward the high-value materials on which future industries are built.

In AI computing and clean energy, lighter, more heat-resistant and more conductive materials determine how well devices perform. MLCCs are essential components in products from smartphones to AI servers, and a single high-end server can use up to 30,000 of them.

"The world is moving toward products that are smaller and lighter, yet stronger and more efficient," said Mr. Narit Therdsteerasukdi, Secretary General of the Thailand Board of Investment. "Producing advanced materials in Thailand is key to building sustainable industrial capacity, reducing reliance on imports, and opening the door for Thai companies to join higher-value supply chains."

Thailand is already a production base for leading component makers, including Japan's Murata Electronics, which holds more than 35 percent of the global MLCC market, and Kyocera AVX Components, the world's top tantalum capacitor maker. Among the new projects, Taiwan's Fultech Fiber Glass makes glass fabric for printed circuit boards, including high-performance grades for AI servers. Jones Tech produces synthetic and natural graphite films that carry heat away from electronic devices.

Beyond electronics, the projects strengthen supply chains for electric vehicles, batteries, and clean energy, from BGN Thai's coated foils for lithium-ion batteries and Phinis Well's neodymium magnets for EV motors to Xinyuan Graphite's bipolar plates for hydrogen fuel cells.

CoorsTek Advanced Materials, a subsidiary of US-based CoorsTek - a global leader in engineered ceramics for the semiconductor and aerospace industries - has invested in producing ceramics for automotive pressure sensors and silicon nitride balls for hybrid bearings in EVs and wind turbines. Golden Egret Cemented Carbide is making tungsten carbide powders for precision cutting tools, reinforcing Thailand's base for high-precision manufacturing.

"The advanced materials industry taking root in Thailand today is the foundation of tomorrow's supply chains in electronics, EVs, batteries, and clean energy," Mr. Narit said. "The BOI will keep building this investment base, strengthening upstream materials and components, and supporting R&D, technology, and workforce development, to move Thailand from downstream to upstream production and make it the region's advanced materials hub."

Note: USD conversions are based on the Bank of Thailand's average selling rate of approximately 33.76 baht per USD.

Thailand Board of Investment (BOI)

Established in 1966, the Thailand Board of Investment (BOI) has spent six decades promoting high-value investment from both foreign and Thai investors, strengthening the country's competitiveness and driving its transition toward a sustainable, balanced new economy.

Investment Services Center - PR Section, Office of the Board of Investment (BOI)

555 Vibhavadi-Rangsit Road, Chatuchak, Bangkok 10900 Tel. +66 (0) 2553 8111, Fax +66 (0) 2553 8222

The issuer is solely responsible for the content of this announcement.

Hashtags: #Thailandboardofinvestment #BOI #FDI #Investment

https://www.boi.go.th/en/index/

SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies,

Announced that the first patient dosing has been completed in a randomized, open-label, multicenter phase 3 clinical study of the company's product, a recombinant humanized anti-CD20/CD3 bispecific antibody (code: JS203),

In combination with chemotherapy compared to rituximab in combination with chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) (the JS203-003-III-DLBCL Study; NCT07808827). This study is the first registrational clinical study for JS203.

DLBCL is one of the most common types of non-Hodgkin lymphoma (NHL), accounting for approximately 40% of adult NHL cases in China. According to GLOBOCAN 2022 statistics, there are approximately 45,000 new cases of DLBCL in China each year, and the incidence rate shows a slow increasing trend. DLBCL is characterized by high aggressiveness and rapid progression. A retrospective study in an Asian population showed that, even after active treatment, patients with relapsed or refractory DLBCL had a median overall survival (mOS) of over one year and a 5-year survival rate of approximately 30%, which necessitates the exploration of more proactive and effective treatment options.

JS203 is a recombinant humanized anti-CD20/CD3 bispecific antibody self-developed by Junshi Biosciences. It consists of anti-CD20 segment and anti-CD3 segment. By associating and activating lymphoma cells (binding to CD20) and T cells (binding to CD3), JS203 can enable T cells to kill lymphoma cells effectively.

Results from a phase 1 clinical study showed that, for JS203 monotherapy at the recommended phase 2 dose (RP2D) administered with step-up dosing (SUD) to 30 mg for the treatment of patients with CD20-positive relapsed or refractory B-cell non-Hodgkin lymphoma, the objective response rate (ORR) reached 72.4%. Among patients with DLBCL, the ORR was 69.7%, and the complete response rate CRR was 39.4%, with persistent relief observed. Meanwhile, the overall safety profile was manageable, with a cytokine release syndrome (CRS) incidence rate of only 27.3% and no occurrence of immune effector cell-associated neurotoxicity syndrome (ICANS).

The JS203-003-III-DLBCL Study is a randomized, open-label, multicenter phase 3 clinical trial, with Professor Yuqin SONG of Beijing Cancer Hospital serving as the principal investigator. It aims to compare the efficacy and safety of JS203 in combination with chemotherapy compared to rituximab in combination with chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma. The study plans to enroll 282 subjects, with overall survival (OS) as its primary endpoint. This study is the first registrational clinical study for JS203.

The JS203-003-III-DLBCL study team commented: "Early clinical studies have shown encouraging efficacy and a favorable safety profile for JS203 in combination with chemotherapy in patients with R/R DLBCL, reinforcing our confidence in the ongoing Phase 3 study. We are committed to advancing the study with rigor and efficiency, with the aim of making a new treatment option available to patients as soon as possible."

About JS203

JS203 is a recombinant humanized anti-CD20/CD3 bispecific antibody self-developed by Junshi Biosciences. CD20 is a B lymphocyte restricted differentiation antigen and one of the most successful targets for B-cell lymphoma treatment. CD3 is an important marker on the surface of T cells, and the main mechanism of T cell engaging bispecific antibodies is using CD3 as a mediator to activate T cells to specifically attack tumor cells. JS203 consists of anti-CD20 segment and anti-CD3 segment. By associating and activating lymphoma cells (binding to CD20) and T cells (binding to CD3), JS203 can enable T cells to kill lymphoma cells effectively. To date, a Phase 3 clinical study evaluating JS203 in combination with chemotherapy versus rituximab in combination with chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) is ongoing.

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. With our outstanding capacity for innovative drug discovery, strong biotechnology R&D capability, and large-scale production capacity, we have successfully developed a drug candidate portfolio with global competitiveness and a well-structured research pipeline, which covers therapeutic areas including cancer, autoimmune, metabolic, and infectious diseases. Our innovative field spans cutting-edge therapeutic modalities, including mAbs, small-molecule drugs, ADCs, bsAb/msAb, fusion proteins, nucleic acid drugs and vaccines.

Five of the company's products have received marketing authorizations in China and international markets, one of which is toripalimab, China's domestically developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in over 50 countries and regions including China, the US, and Europe.

With a mission of "providing patients with world-class, trustworthy, affordable, and innovative drugs," Junshi Biosciences is "In China, For Global." The company currently employs more than 3,000 people worldwide. Headquartered in Shanghai, China, it has a business presence in multiple countries and regions around the world. For more information, please visit: http://www.junshipharma.com.

Copyright 2026 GlobeNewswire, Inc.

*The 2026 iCAUR International User Summit opened on October 19 in Wuhu, China, under the theme "Classic Never Fades | Make It Yours."

*The iCAUR V25 made its global debut and officially went on sale worldwide. Together with the V23 and V27, it rounds out the V-Series lineup, bringing the Future Classic Design concept to life across a comprehensive product portfolio.

*Three officially customized V-Series models will enter global markets. At the summit, 20 customized vehicles were showcased, highlighting the creativity of users from different communities and markets.

WUHU, China, Oct. 23, 2026 (GLOBE NEWSWIRE) -- The 2026 iCAUR International User Summit opened in Wuhu, China, on October 19, bringing together more than 500 user representatives from around the world, alongside partners and international media.

Under the theme "Classic Never Fades | Make It Yours," the five-day event brings together product experiences, vehicle customization, user stories and ecosystem activities, highlighting how iCAUR connects its design philosophy with the interests and creativity of users around the world.

The summit showcases the iCAUR V25, three officially customized V-Series models, and 20 customized vehicles. Visitors can also explore the iCAUR brand showroom, take part in a smart factory tour, and experience the V-Series through multi-scenario test drives. The event also marks the introduction of iCAUR's first group of Brand Ambassadors and highlights the next phase of its global user engagement initiative, Club Connect. Through these activities, iCAUR brings together three key elements of its brand: Future Classic Design, customization and a growing network of users who help shape the brand's development.

Building a Global Brand Through Products and Local Connections

Since its launch, iCAUR has expanded into more than 40 countries and regions worldwide. The V23 has surpassed 100,000 units in cumulative global sales and received the Red Dot Design Award in 2026, while the V27 won the Best Interior Design Award in the Premium Car Category at the 2026 Torino Automotive Design Award (TADA).

These milestones mark an important stage in the brand's international development. As iCAUR continues to expand into new markets, it is also working with local partners to strengthen sales and service networks and build lasting relationships with users.

At the summit, Ronna, CEO of iCAUR International, shared the brand's view that entering a market is only the beginning. Long-term growth comes from understanding users, listening to their ideas and creating experiences that give them more ways to engage with the brand.

iCAUR V25 Expands the V-Series

The iCAUR V25 takes center stage at the summit, further expanding the V-Series alongside the V23 and V27. Built around the brand's Future Classic Design philosophy, the V25 combines a distinctive boxy silhouette and classic round headlights with modern technology and capabilities for a range of driving scenarios.

At the event, Dr. Su Jun, Vice President of Chery Automobile Co., Ltd., explained the thinking behind the V25 through three principles: restraint, capability and freedom.

The design retains the V-Series' recognizable proportions and signature styling rather than following short-term trends. Its i-SWIFT Agile Handling Platform, Golden REEV powertrain and i-AWD system support a variety of driving conditions, from urban roads to more challenging terrain.

The V25 also leaves room for personalization, with more than 20 ecosystem interfaces. Other features include a 1.8-ton towing capacity, 6 kW vehicle-to-load (V2L) capability, 66.4% space efficiency, 41 storage spaces and a body made of 80% high-strength steel.

Together, the V23, V25 and V27 show how Future Classic Design can take different forms across the V-Series, combining a recognizable design identity with modern technology and opportunities for personal expression.

Three Officially Customized Models Showcase Different Personalities

Customization is a key highlight of the summit, with three officially customized V-Series models presented alongside 20 customized vehicles developed with users and partners.

Each of the three officially customized models reflects a different interest and lifestyle. The V23 Forge brings urban individuality to life with a muscular widebody stance and gloss-black accents, while retaining the V23's playful character. The V25 Game Changer celebrates the freedom to play, combining the V25's classic toughness with gaming-inspired details. The V27 Sun Roam draws inspiration from 1980s off-road vehicles and vintage cameras, pairing rugged proportions with carefully crafted details.

The three models are planned for introduction in global markets by early 2027, through KD production or dealer-installed packages, subject to local regulations and market conditions. Beyond the official builds, the 20 customized vehicles on display demonstrate how users and partners bring their own ideas to the V-Series. Visitors can explore different styles, learn about customization details and exchange ideas with the teams behind the vehicles.

Customization is already an important part of the iCAUR user experience. According to the brand, 50% of its users worldwide customize their vehicles. Their choices and ideas also provide inspiration for the brand's future products and customization offerings.

Looking ahead, iCAUR plans to introduce dedicated customization spaces in its showrooms, giving customers more opportunities to explore personalization options. The brand also plans to present a customized classic vehicle alongside new models at future model launches, offering inspiration for different ways to make an iCAUR their own.

The brand is continuing to expand its customized vehicle lineup, develop accessories suited to local markets and establish quality and safety validation mechanisms for customization offerings. These efforts aim to make customization more accessible while safeguarding quality and safety.

Connecting Vehicles with Lifestyle Experiences

The iCAUR brand showroom brings together vehicle customization, classic lifestyle elements, and user co-creation, offering visitors a broader view of the brand beyond its vehicles.

Body accessories, outdoor equipment and lifestyle products demonstrate how the vehicle can connect with different interests and everyday activities. Music, travel, surfing and cycling elements reflect the varied ways users explore their interests and express their individuality.

The summit also includes a smart factory tour, giving participants a closer look at iCAUR's manufacturing processes and quality management. During the event, the V-Series multi-scenario test-drive activities will give participants the opportunity to experience the V25 and V27 across different road conditions, including wavy roads, mud, uneven terrain, S-curves and other driving challenges. Activities involving smart ecosystem partner AiMOGA and green community initiatives are also scheduled as part of the five-day program.

Together, these experiences allow users and partners to explore the vehicles, understand the brand's design approach and see how iCAUR connects its products with different lifestyles and interests.

From Official User Clubs to Global Club Connect

For iCAUR, the relationship with users continues well beyond vehicle delivery. The brand has established official user clubs in nine countries, bringing owners together to share experiences and connect through common interests.

In 2027, iCAUR plans to expand this approach through its global Club Connect initiative, bringing together more users across markets, encouraging the exchange of ideas, and using user feedback to inform future products and experiences.

The summit also marks the introduction of iCAUR's first group of Brand Ambassadors. These users are recognized for their creativity, passion, and contributions to the brand. Through Club Connect, iCAUR plans to continue selecting ambassadors who can share their experiences, contribute to brand activities, and inspire other users in their markets.

User participation also extends to customization. Ideas from users may inspire future officially customized models for global markets, creating further opportunities for users to contribute to how iCAUR products evolve.

As the brand continues its international expansion, iCAUR aims to reach more than 70 markets by 2027. Alongside market development, it will continue working with local partners to strengthen sales and service networks and to develop user engagement in different regions.

The 2026 iCAUR International User Summit brings these priorities together through iCAUR's vehicles, customized builds, hands-on experiences, and growing network of user clubs and Brand Ambassadors.

Guided by "Classic Never Fades" and "Make It Yours," iCAUR continues to develop its Future Classic Design philosophy while giving users more opportunities to express their individuality and contribute to the brand. For iCAUR, delivery is not the end of the story, but the starting point for what users can make of their iCAUR.

About iCAUR

Chery Group's iCAUR is a new energy automotive brand driven by Future Classic Design and technology. Guided by its design philosophy, iCAUR combines classic design elements with modern aesthetics and technology to develop distinctive vehicles for urban mobility and outdoor exploration. With a focus on product innovation and customization, iCAUR offers diverse vehicle choices and personalization options, extending its brand experience through user services and a growing range of user engagements initiatives.

iCAUR's product portfolio is supported by technologies including i-AWD intelligent electric all-wheel drive and the REEV Golden Range Extender, delivering performance and capability for a range of driving conditions. With a growing presence in more than 40 markets worldwide, iCAUR continues to expand its international business and user engagements, guided by its brand belief: Classic Never Fades.

Copyright 2026 GlobeNewswire, Inc.

Kolaborasi ini bertujuan untuk meningkatkan perencanaan uji klinis dan memperluas akses pasien ke penelitian yang sesuai dengan biomarker mereka di Australia

Sorotan

*Kolaborasi ini bertujuan untuk mempercepat penelitian onkologi presisi di Australia

*Menggabungkan pengalaman Fortrea dalam uji klinis onkologi dengan program Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) milik Omico

*Bersama-sama, Fortrea dan Omico menawarkan proses pemilihan lokasi penelitian klinis yang lebih efisien serta akses yang lebih cepat bagi pasien dengan menghubungkan mereka ke uji klinis yang relevan berdasarkan biomarker

DURHAM, North Carolina dan SYDNEY, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) ("Perusahaan"), organisasi penelitian berbasis kontrak ("CRO") global terkemuka, dan Omico, organisasi terkemuka di Australia dalam skrining onkologi presisi dan pencocokan pasien dengan uji klinis, hari ini mengumumkan kolaborasi untuk mempercepat penelitian onkologi presisi dengan membantu menghubungkan pasien kanker ke uji klinis yang sesuai dengan biomarker mereka.

Kolaborasi ini menggabungkan jaringan onkologi presisi Omico dengan pengalaman ilmiah dan uji klinis Fortrea. Kerja sama ini bertujuan untuk meningkatkan perencanaan penelitian, pemilihan lokasi penelitian, dan perekrutan pasien guna memperluas akses ke penelitian onkologi berbasis biomarker secara global.

Melalui inisiatif ini, Omico akan mendukung kebutuhan klien Fortrea dalam pengembangan obat onkologi dengan menyediakan akses ke informasi populasi pasien, termasuk profil genomik, kemampuan pencocokan pasien dengan uji klinis, data onkologi dunia nyata, serta jalur rujukan pasien di Australia. Negara ini merupakan salah satu lokasi penting untuk kegiatan penelitian klinis onkologi, baik pada fase awal maupun fase akhir.

Kolaborasi ini akan menggabungkan pengalaman Fortrea dalam pengembangan obat onkologi dengan program unggulan Omico, Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT), yang merupakan inisiatif genomik kanker terbesar di Australia. PrOSPeCT dirancang untuk menyediakan pemeriksaan profil molekuler dan membantu mencocokkan pasien dengan uji klinis berbasis biomarker serta terapi bertarget.

"Melalui kolaborasi kami dengan Omico, kami berupaya menjangkau pasien yang tepat untuk penelitian yang sesuai secepat mungkin," ujar Oren Cohen, M.D., Chief Medical Officer di Fortrea. "Pengembangan onkologi modern menuntut tingkat presisi yang semakin tinggi untuk mencocokkan jenis kanker tertentu dengan terapi yang paling berpotensi memberikan manfaat bagi pasien, dan melakukannya secepat mungkin. Kerja sama kami dengan Omico meningkatkan kemampuan kami untuk lebih cepat mengidentifikasi pasien yang tepat bagi penelitian berbasis biomarker di Australia serta membantu memajukan pengobatan presisi bagi penderita kanker."

Omico telah membangun salah satu ekosistem onkologi presisi terluas di Australia yang menggabungkan pemeriksaan profil molekuler, bukti dunia nyata, program penelitian kohort, serta jaringan peneliti dan lokasi penelitian klinis di seluruh Australia. Omico melaporkan bahwa basis data klinis dan genomiknya mencakup lebih dari 23.000 pasien yang telah memberikan persetujuan. Selain itu, Omico telah menerima rujukan dari lebih dari 1.600 tenaga medis di seluruh Australia.

"Australia berada di posisi yang tepat untuk mendukung uji klinis berbasis biomarker secara global berkat infrastruktur penelitian onkologi presisi nasional, keahlian, dan jaringan yang telah dibangun Omico," ujar Profesor David Thomas, Chief Science and Strategy Officer di Omico. "Dengan menggabungkan kemampuan kami dalam pengelolaan data dan pencocokan pasien dengan uji klinis di tingkat nasional serta keahlian Fortrea dalam pengembangan klinis global. Dengan begitu, kami dapat membantu sponsor internasional mengidentifikasi populasi pasien yang relevan, merencanakan uji klinis secara lebih efektif, dan mendukung perekrutan pasien yang tepat sasaran."

Keahlian Fortrea di bidang onkologi ditopang oleh ribuan tenaga profesional operasional dan didukung oleh lebih dari 50 dokter spesialis onkologi yang tergabung dalam jajaran stafnya. Kolaborasi ini berlangsung di tengah perkembangan obat onkologi modern yang semakin mendorong fokus pada pengobatan presisi, pengembangan obat berbasis biomarker, dan identifikasi pasien secara tepat sasaran. Melalui kerja sama ini, Fortrea dan Omico dapat meningkatkan efisiensi pemilihan lokasi penelitian serta kemampuan untuk mencocokkan pasien dengan penelitian yang sesuai berdasarkan data genomik unik mereka. Hal ini memungkinkan lebih banyak pasien di Australia untuk berpartisipasi dalam penelitian yang disesuaikan dengan kondisi kesehatan masing-masing.

Tentang Fortrea

Fortrea (Nasdaq: FTRE) adalah penyedia solusi pengembangan klinis global terkemuka untuk industri ilmu hayati. Kami bermitra dengan perusahaan biofarmasi, bioteknologi, alat medis, dan diagnostik besar dan sedang berkembang untuk mendorong inovasi layanan kesehatan yang mempercepat terapi yang mengubah hidup pasien. Fortrea menyediakan manajemen uji klinis fase I-IV, farmakologi klinis, dan layanan konsultasi. Solusi Fortrea memanfaatkan pengalaman selama tiga dekade yang mencakup lebih dari 20 area terapeutik, antusiasme terhadap ketelitian ilmiah, wawasan luar biasa, serta jaringan situs peneliti yang kuat. Tim kami yang berbakat dan beragam, yang bekerja di sekitar 100 negara, memiliki skala yang memadai untuk memberikan solusi yang terfokus dan tangkas kepada klien di seluruh dunia. Pelajari lebih lanjut bagaimana Fortrea menyederhanakan proses pengembangan obat di Fortrea.com dan ikuti kami di LinkedIn, X, dan Bluesky.

Tentang Omico

Omico adalah organisasi penelitian nasional independen dan nirlaba yang mengubah cara kita melawan kanker. Kami berupaya meningkatkan hasil pengobatan bagi penderita kanker di Australia dengan menyediakan akses yang setara ke layanan onkologi presisi serta menerapkan kemajuan ilmiah dalam perawatan klinis dan penelitian. Kami juga menghasilkan bukti yang diperlukan sebagai dasar penyusunan kebijakan kesehatan dan reformasi sistem kesehatan. Melalui kerja sama dengan lembaga kanker terkemuka, peneliti, klinisi, mitra industri, kelompok advokasi, dan pemerintah di Australia, kami mempercepat pemeriksaan profil molekuler, uji klinis berbasis biomarker, pengelolaan risiko kanker yang dipersonalisasi, serta bukti dunia nyata.

Tentang PrOSPeCT

PrOSPeCT merupakan inisiatif onkologi presisi terbesar di Australia. Program ini diselenggarakan oleh Omico bersama jaringan nasional mitra layanan kesehatan, penelitian, dan industri. Program ini memberikan akses kepada warga Australia yang memenuhi syarat untuk menjalani pemeriksaan profil molekuler serta pencocokan dengan uji klinis dan terapi berbasis biomarker (tanpa biaya bagi pasien). Selain itu, program ini menghasilkan data klinis, genomik, pengobatan, dan hasil pengobatan untuk memajukan penelitian, meningkatkan kualitas perawatan kanker, serta menjadi dasar penyusunan kebijakan kesehatan di masa depan.

Kontak Fortrea:

Galen Wilson (Media) - 703-298-0802, media@fortrea.com

Kate Dillon (Media) - 646-818-9115, kdillon@prosek.com

Tracy Krumme (Investor) - 984-385-6707, Tracy.Krumme@fortrea.com

Kontak Omico :

Kym Bramich (Komunikasi) +61 414 795 087, k.bramich@omico.org.au

Copyright 2026 GlobeNewswire, Inc.

Featuring AI pioneer Dr. Kevin Knight

Guangzhou, China, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Tec-Do today hosted Technology Growth Conference 2026 (TGC 2026) in Guangzhou under the theme "AI is Profitable." Featuring AI pioneer Dr. Kevin Knight and speakers from OpenAI, Google, Alibaba, ByteDance and Tencent, the conference explored how AI can deliver measurable business value.

At the event, Tec-Do launched Navos Pro, which the company describes as the industry's first Pro-Agent. Built around three attributes-Professional, Proactive and Profitable-the product advances Tec-Do's results-driven approach to AI for Work.

From AI Capabilities to Business Results

In his opening keynote, "From Language to Action: The Next Leap in AI," Dr. Knight drew on his academic and industry experience to identify AI for Work as a major direction for AI applications.

Shuhao Li, Founder and CEO of Tec-Do, outlined a multitrillion-dollar opportunity across three areas of enterprise spending: marketing and sales, coding and product development, and management. These correspond to AI for Growth, AI for Innovation and AI for Administration. Within this framework, Li positioned Navos Pro as a leading contender in AI for Growth.

"We focus exclusively on results-driven AI for Work," Li said.

Designed for cross-border ecommerce, international trade, marketing and business analysis, Navos Pro combines:

Professional: Builds a private knowledge base from a brand's website and retains business context to produce outputs aligned with its commercial objectives.

Proactive:Monitors data around the clock to identify opportunities and recommend actions, while people retain decision-making authority.

Profitable: Connects strategy, creative development and advertising execution to measurable outcomes, including gross merchandise value (GMV) and return on investment (ROI).

These capabilities are supported by specialized 32B, 27B and 5B parameter models, industry knowledge, more than 70 MCP integrations and over 100 skills. According to Tec-Do, the platform monitors more than 1 billion data points daily. A Learning Loop connects results with strategy optimization, while Navos RSI uses agentic reinforcement learning to improve its Agent Harness.

The architecture supports deployment across markets, channels and industries. The product portfolio includes Navos Lite and Navos Pro, covering the end-to-end international marketing workflow.

From Responding to Initiating Work

Li described the evolution from Chatbots to Copilots to Pro-Agents as a shift in who initiates work: from responding to requests, to assisting execution, to proactively identifying opportunities and delivering growth. He argued that the AI industry is moving from providing capabilities to proving business value.

Drawing on its experience serving hundreds of thousands of brands expanding internationally, Tec-Do is extending this approach through partnerships. The company said it became one of the first global technology partners for ChatGPT Ads in July 2026, helping brands raise ROI to 2.5 times previous levels. In August, it partnered with Tencent WorkBuddy to apply AI capabilities to international advertising.

Li said AI for Growth is the first step, with plans to extend Tec-Do's capabilities into AI for Innovation and AI for Administration.

Advancing AI Commercialization

Lorry Destainville, Monetization Partnerships at OpenAI, shared perspectives on ChatGPT's commercialization. He said ChatGPT reaches 1.2 billion users weekly and that OpenAI is exploring Sponsored Agents and Visual Ads. He also thanked Tec-Do for collaborating on practical, measurable AI growth tools for brands.

Three panels, moderated by Maeve Zhang, Vice President of Branding and Public Relations at Tec-Do, examined AI's impact on business, international expansion and ecosystem collaboration, bringing together technology providers, entrepreneurs and investors.

The conference concluded with Eileen Nie, Founding Partner and Head of Ecosystem Incubation and Strategic Investment at Tec-Do, announcing the Pro-Agent Global Challenge. The initiative invites entrepreneurs worldwide to submit projects in agent architecture, AI marketing, AI content gateways and computing infrastructure, offering access to capital, industry resources and global growth channels.

About Tec-Do

Founded in 2017, Tec-Do is a leading AI marketing company delivering results-centric marketing solutions for global business growth. Powered by Tec-Chi multi-modal large language models (MLLMs) and Marketing Multi-Agent Platform Navos, the company delivers end-to-end marketing solutions through a suite of AI-native, performance-driven products.

These products restructure and autonomize mission-critical marketing processes-including market intelligence, content generation, campaign delivery, and performance optimization-across global media channels. In 2025, Tec-Do served over 100,000 advertisers, representing a diversified customer base that spans e-commerce, gaming, entertainment, and local commerce.

Copyright 2026 GlobeNewswire, Inc.

A statue tells the story of "Half a Quilt" in Shazhou, Hunan Province, central China. /VCG

BEIJING, Oct. 23, 2026 (GLOBE NEWSWIRE) -- CGTN menerbitkan sebuah artikel untuk memperingati 90 tahun kemenangan Tentara Merah dalam Mars Panjang. Berangkat dari kisah "Separuh Selimut", artikel tersebut menyoroti pesan Presiden Xi Jinping agar semangat Mars Panjang terus dihidupkan dalam perjalanan modernisasi Tiongkok.

Artikel tersebut juga menggali pandangan para pengamat internasional mengenai pelajaran yang dapat dipetik negara-negara Selatan Global dari pengalaman pembangunan Tiongkok.

Pada musim dingin 1934, di tengah perjalanan Mars Panjang, tiga prajurit perempuan Tentara Merah tiba di rumah Xu Jiexiu, seorang warga miskin di Desa Shazhou, Provinsi Hunan. Melihat keluarga Xu hampir tak punya apa-apa untuk menghangatkan diri, ketiga prajurit itu memotong satu-satunya selimut mereka menjadi dua dan meninggalkan separuhnya untuk Xu sebelum melanjutkan perjalanan.

Kebaikan tersebut kemudian dikenal sebagai kisah "Separuh Selimut," sebuah simbol abadi tentang ikatan antara Partai Komunis Tiongkok (PKT) dan rakyat.

Presiden Tiongkok Xi Jinping kembali mengangkat kisah tersebut pada hari Kamis dalam acara peringatan 90 tahun kemenangan Mars Panjang Tentara Merah.

"Hanya dengan mengingat sejarah, kita dapat menciptakan masa depan yang lebih cerah," ujar Xi. Xi menegaskan bahwa dukungan rakyat menjadi kunci kemenangan Mars Panjang, sekaligus menyerukan agar Tiongkok terus menorehkan pencapaian baru dalam perjalanannya menuju modernisasi.

Dari separuh selimut menuju kehidupan yang lebih baik

Saat mengunjungi balai pameran bertema "Separuh Selimut" pada September 2020, Xi menyerukan agar partai senantiasa bersatu dengan rakyat dalam menempuh Mars Panjang di era baru.

Kini, komitmen tersebut tercermin dalam berbagai upaya untuk meningkatkan taraf hidup rakyat. Desa tersebut memberikan tunjangan bulanan bagi warga berusia 60 tahun ke atas dan menanggung separuh iuran asuransi kesehatan dasar warganya. Selain itu, program layanan ramah anak juga telah diperluas hingga menjangkau sembilan desa di sekitarnya.

Bagi keturunan Xu, perubahan tersebut benar-benar terasa nyata. Cucunya, Zhu Xiaohong, dulu pernah hidup dalam kemiskinan. Berkat dukungan otoritas PKT setempat, ia mengikuti pelatihan kuliner lalu membuka sebuah restoran.

"Dulu Tentara Merah memberi kami separuh selimut; kini Partai tersebut memberi kami kehidupan yang bahagia," tutur Zhu.

Josef Gregory Mahoney, profesor politik dan hubungan internasional di East China Normal University, berbicara kepada CGTN tentang makna Mars Panjang. Menurutnya, pelajaran abadi dari peristiwa tersebut adalah bahwa kepercayaan publik dibangun dengan memenuhi kebutuhan masyarakat serta menanggung kesulitan bersama-sama dan berbagi pencapaian bersama-sama. Kini, upaya pengentasan kemiskinan dan revitalisasi perdesaan pun bergantung pada hal yang sama, yakni memastikan rakyat merasakan manfaat nyata dalam kehidupan mereka.

Seperti yang ditegaskan Xi pada hari Kamis, keteguhan memegang cita-cita dan tujuan Partai serta kedekatan dengan rakyat merupakan kunci untuk meraih pencapaian-pencapaian baru.

Mars Panjang Baru

Kini, Shazhou merintis jalannya sendiri dalam Mars Panjang baru dengan mengubah warisan revolusioner dan sumber daya ekologisnya menjadi peluang bagi pembangunan berkelanjutan dan kemakmuran bersama.

Desa tersebut telah memugar situs-situs bersejarah revolusi dan mengembangkan wisata merah. Di saat yang sama, kualitas lingkungan tempat tinggal warga juga terus diperbaiki melalui pengelolaan sungai, pengolahan air limbah, dan pengumpulan sampah. Wilayah di sekitarnya juga mendorong budi daya buah-buahan khas serta memadukan pertanian dengan pariwisata. Langkah ini membuka peluang baru bagi usaha lokal dan lapangan kerja, sekaligus menopang pembangunan perdesaan yang lebih berkelanjutan.

Hasilnya pun tercermin dalam statistik setempat. Shazhou resmi keluar dari daftar desa miskin pada tahun 2018. Pada tahun 2025, pendapatan bersih per kapita tahunan warga desa telah meningkat dari kurang dari 4.000 yuan (sekitar $634) pada tahun 2012 menjadi lebih dari 25.000 yuan. Sementara itu, pendapatan kolektif desa yang semula nyaris nol kini telah melampaui 1 juta yuan.

Pakar asal Brasil, Rafael Henrique Zerbeto, yang turut serta dalam program napak tilas Mars Panjang, mengatakan bahwa mengutamakan kepentingan rakyat tetap menjadi hal yang sangat penting bagi pembangunan Tiongkok. Mulai pelestarian warisan revolusioner hingga pengembangan industri khas daerah yang meningkatkan pendapatan warga, ia menyaksikan bagaimana Tiongkok berhasil mengubah semangat Mars Panjang menjadi kekuatan pendorong pembangunan berkualitas tinggi.

Survei terbaru CGTN terhadap 12.000 responden di 41 negara menunjukkan bahwa 63,9% responden global melihat adanya kaitan erat antara kepemimpinan PKT dan berbagai pencapaian pembangunan Tiongkok. Di kalangan responden dari negara-negara Selatan Global, angka tersebut bahkan mencapai 71,4%.

Bagi Mahoney, Mars Panjang juga memberikan pelajaran bagi negara-negara Selatan Global: jalur pembangunan harus disesuaikan dengan kondisi setempat, sementara tantangan bersama menuntut kerja sama internasional. Secara lebih luas, Mars Panjang mengajarkan bahwa kemajuan yang berkelanjutan berawal dari kemampuan suatu negara untuk bertumpu pada kekuatannya sendiri, sekaligus bekerja sama dengan pihak lain demi mencapai tujuan bersama.

Sebagaimana disampaikan Xi dalam pidato peringatannya, semangat Mars Panjang tetap menjadi "harta yang tak ternilai sekaligus kekuatan pendorong yang besar, yang menginspirasi kita untuk menaklukkan berbagai kesulitan dan terus melangkah maju dengan penuh keberanian."

Copyright 2026 GlobeNewswire, Inc.

Miami, Oct. 23, 2026 (GLOBE NEWSWIRE) --

The news in brief:

Muck Rack was named as a Leader in the 2026 Gartner Magic Quadrant for PR and Media Monitoring Tools, the first Magic Quadrant Gartner has published for this market.

It was Muck Rack's first evaluation for the report.

Muck Rack is a single platform for communications teams that connects journalist research, pitching, press release distribution, monitoring of more than 600,000 global sources, sentiment tracking and AI visibility measurement with Generative Pulse.

Muck Rack has expanded across Europe, with teams in Ireland, Bulgaria and the UK.

Muck Rack, the AI communications platform, today announced it has been named as a Leader in the 2026 Gartner Magic Quadrant for PR and Media Monitoring Tools, the first Magic Quadrant Gartner has published for this market.

Muck Rack views the report as a milestone for the communications profession. Muck Rack believes earned media and communications technology is now a category that enterprise buyers procure with the same rigor they apply to CRM or marketing automation.

"We're honored to be named as a Leader the first time we were evaluated, but the bigger story is that PR technology now has its own Magic Quadrant," said Greg Galant, cofounder and CEO of Muck Rack. "For every communications team that's had to make the case for earned media, narrative and reputation, that's validation. Enterprises now invest in communications seriously, and they expect the tools behind it to hold up to serious scrutiny."

Muck Rack believes that scrutiny reflects how much the job has changed. Communications leaders now pick up signals from news, social platforms, podcasts, newsletters and generative AI models. In Muck Rack's view, PR professionals need more than monitoring to understand the narrative, act quickly and prove their value to the business.

Muck Rack was built from the start as a single platform for communications teams, connecting the entire PR workflow in one system of record. Teams can find journalists, monitor more than 600,000 global sources, track sentiment, pitch and distribute news, and measure how their brand appears in AI-generated answers with Generative Pulse. All of it runs on the same intelligence engine and the same verified media data, maintained by Muck Rack's editorial team and by journalists themselves. AI takes on the heavy lifting of research, filtering, summarization and targeting, and each part of the platform strengthens the next: monitoring sharpens outreach, outreach is tied to the coverage it produces, and reporting shows teams what to refine next.

The release also added agentic coverage analysis, AI summaries, multi-subject monitoring, expanded Curation Engine capabilities, flexible analytics, Global Tags, broader broadcast and licensed content monitoring, redesigned Coverage Reports and an MCP integration. Together, these updates cut the manual work of organizing and analyzing coverage. The company has also expanded across Europe, with a support team in Ireland, an insights operation in Bulgaria, and sales and customer success in the UK.

Check out Muck Rack by requesting a demo.

Gartner Report, Magic Quadrant for PR and Media Monitoring Tools, By Amber Boyes, Paul Swiergosz, etc., October 2026. 

GARTNER and MAGIC QUADRANT are the trademark of Gartner, Inc. and/or its affiliates.

Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner's business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose. 

About Muck Rack

Muck Rack is the AI communications platform where trusted data, human expertise, and embedded intelligence come together to drive clarity, speed and impact. Thousands of companies turn to Muck Rack to make sense of the media conversation around them and understand how their brand shows up in the news and in AI-generated answers.

Muck Rack combines global media monitoring, Generative Engine Optimization (GEO) insights, social listening, trusted media data, AI automation, and analyst advisory to help organizations manage reputation, act quickly, and prove their impact across the PR workflow. Thousands of journalists also use Muck Rack's free tools to showcase their work and analyze the news. Learn more at muckrack.com.

We're Hiring!

Copyright 2026 GlobeNewswire, Inc.

*WeRide was named among WICV 2026's "Top 10 Automotive AI Application Cases of 2026" for its Physical AI flywheel powered by GENESIS and WITT.

*Founder and CEO Dr. Tony Han shared WeRide's approach to applying L4 autonomous driving technology to L2 advanced driver-assistance systems, emphasizing intelligence density and safety.

*WeRide continues to expand real-world deployment across L2 to L4, with operations in more than 60 cities across 13 countries and an L4 fleet of approximately 3,600 vehicles.

BEIJING, Oct. 23, 2026 (GLOBE NEWSWIRE) -- WeRide (NASDAQ: WRD, HKEX: 0800), a global leader in autonomous driving technology, has been named among the "Top 10 Automotive AI Application Cases of 2026" at the 2026 World Intelligent Connected Vehicles Conference (WICV). The recognition highlights WeRide's innovative Physical AI flywheel powered by WeRide GENESIS and WeRide WITT, demonstrating how the company is translating cutting-edge AI technologies into large-scale commercial applications.

The selected case of WeRide's Physical AI flywheel, highlights the practical application of the collaborative application of cutting-edge AI technologies in autonomous driving development. At its core, the flywheel brings together WeRide GENESIS, WeRide's proprietary general-purpose simulation model, and WeRide WITT, WeRide's Physical AI Cognitive Foundation Model.

WeRide WITT extracts and validates physical facts from real-world road data, while WeRide GENESIS uses these insights to generate high-fidelity simulation scenarios that adhere to real-world physical laws, strengthening training in complex driving scenarios and long-tail situations. Together, the two models empower vehicle-side models, improve development efficiency and adaptability to complex scenarios, and support the deployment of autonomous driving technology across cities and vehicle platforms.

Focusing on the path to scaled production of autonomous driving, Dr. Tony Han, Founder and CEO of WeRide, delivered a keynote titled "The Critical Leap Toward Scaled Deployment of Autonomous Driving" at the conference's Key Technology Forum, sharing WeRide's experience in applying L4 expertise to L2 advanced driver-assistance systems (ADAS).

Dr. Han highlighted "intelligence density" as a key metric for evaluating ADAS solutions: how much intelligence each TOPS of computing power can deliver. The goal is to achieve a higher level of intelligent driving with limited computing resources. He also emphasized that investing in safety is essential to earning user trust and building long-term brand value. As the technology advances and its applications expand, safety must remain a priority at every stage, protecting not only passengers inside the vehicle but also every road user outside it.

WICV 2026 was held in Yizhuang, Beijing, from October 21 to 23, and was co-hosted by China's Ministry of Industry and Information Technology, Ministry of Transport, and the People's Government of Beijing Municipality. This year's conference was themed "Pooling Wisdom, Boundless Connectivity: Advancing Steadily Towards a New Era of Automated Driving". The conference has been held annually since 2018 and serves as a major industry event for intelligent connected vehicles, as well as an important platform for policy development and international cooperation.

WeRide's autonomous driving technologies were also showcased in real-world applications during the conference. During WICV 2026, WeRide deployed more than a dozen Robotaxis and Robobuses, providing autonomous ride experiences and shuttle services for attendees. The nearly 7-kilometer Robotaxi experience route started and ended at the main venue, while Robobuses provided shuttle services connecting conference venues and visitor destinations, including Yonghui Building, BAIC BluePark, Rocket Street, and Robot World.

Today, WeRide has commercialized its full-stack autonomous driving technologies spanning L2 to L4, with operations spanning more than 60 cities across 13 countries worldwide. Its L4 autonomous driving fleet comprises approximately 3,600 vehicles, supported by extensive operating experience across different cities and real-world use cases.

WeRide's autonomous passenger vehicles are already operating publicly in major global cities, including Guangzhou, Beijing, Abu Dhabi, Dubai, Singapore, Riyadh, and Zurich. Through global mobility platforms such as Uber and Grab, as well as local partners including SBB, ioki and TXAI, WeRide is integrating autonomous driving into more urban transportation networks and will soon launch services in additional markets including Spain and Denmark.

WeRide's L4 autonomous driving technology is also empowering mass-produced passenger vehicles through shared technology architecture. WRD 3.0, WeRide's one-stage end-to-end L2++ ADAS solution, has been deployed on models including the Chery Exeed Sterra, GAC AION N60, AION i60, and GAC Trumpchi Y7. To date, WRD 3.0 has secured production design wins across more than 30 vehicle models, bringing advanced driving technologies to a broader consumer base.

As the intelligent connected vehicle industry enters a new phase of development, WeRide will continue to advance Physical AI innovation and promote technological synergies across L2 to L4. Working with global industry partners, WeRide will expand the real-world application of its technologies at scale, translating technological progress into safer and more reliable mobility experiences.

About WeRide

WeRide is a global leader and a first mover in the autonomous driving industry, as well as the first publicly traded Robotaxi company. Our autonomous vehicles have been deployed in over 60 cities across 13 countries. We are also the first and only technology company whose products have received autonomous driving permits in nine markets: China, the UAE, Singapore, France, Switzerland, Saudi Arabia, Belgium, Spain, and the US. Empowered by the smart, versatile, cost-effective, and highly adaptable WeRide One platform, WeRide provides autonomous driving products and services from L2 to L4, addressing transportation needs in the mobility, logistics, and sanitation industries. WeRide was named to Fortune's Change the World lists in 2023, 2025, and 2026, and to the Fortune Future 50 list in 2025.

Safe Harbor Statement

This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to," and similar statements.

Statements that are not historical facts, including statements about WeRide's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in WeRide's filings with the U.S. Securities and Exchange Commission and announcements on the website of the Hong Kong Stock Exchange.

All information provided in this press release is as of the date of this press release. WeRide does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Copyright  2026 GlobeNewswire, Inc.

HONG KONG SAR - Media OutReach Newswire - 23 October 2026 - Louis Vuitton unveils a new hoarding in Hong Kong following the iconic ones on the Champs-?lys?es in Paris in September 2023, in New York in November 2024, and in Shanghai in June 2025 .

Louis Vuitton unveils in October 2026 a spectacular hoarding inspired by one of the House's most emblematic themes: the Art of Travel. Throughout the refurbishment, the fa?ade is transformed into a grand train station, evoking the romance and golden age of travel. In celebration of the 130rh anniversary of the Monogram, this reimagined station will also be decorated with the House's distinctive Monogram motif.

Conceived as a tribute to the House's enduring fascination with travel, and as a nod to Hong Kong's comprehensive transportation history, the installation brings together heritage, imagination and architectural presence. In keeping with Louis Vuitton's commitment to more mindful creation, all materials used in the construction of the fa?ade will later be reused or recycled. Designed to capture the city's vibrant energy, this striking installation will be established as a new monument for all.

About Louis Vuitton

Since 1854, Louis Vuitton has brought unique designs to the world, combining innovation with style, always aiming the finest quality. Today, the House remains faithful to the spirit of its founder, Louis Vuitton, who invented a genuine "Art of Travel" through luggage, bags and accessories which were as creative as they were elegant and practical.

Since then, audacity has shaped the story of Louis Vuitton. Faithful to its heritage, Louis Vuitton has opened its doors to architects, artists and designers across the years, all the while developing disciplines such as ready-to-wear, shoes, accessories, watches, jewellery, beauty, and fragrance. These carefully created products are testament to Louis Vuitton's commitment to fine craftsmanship.

For further information: www.louisvuitton.com

The issuer is solely responsible for the content of this announcement.

Hashtags: #LouisVuitton

*Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional development, commercial and sales-based milestones 

*Zymeworks also eligible to receive tiered high-single-digit to mid-teen royalties on global net sales protected by patents extending into 2040's

*Zymeworks will conduct the Phase 1a monotherapy clinical trial of ZW209 in collaboration with Roche 

*U.S. FDA IND clearance received with additional global regulatory applications planned to support the opening of clinical study sites outside the U.S.

*Transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976

*Conference call with Zymeworks management on October 27 at 8:30 am Eastern Time (ET)

VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that it has entered into a global license and collaboration agreement with Roche for the research, development and commercialization of ZW209, a T cell engager targeting DLL3.

Under the agreement, Zymeworks is eligible to receive an upfront payment of $55 million, a $40 million payment upon initiation of the Phase 1b trial, and additional development, commercial and sales-based milestone payments of up to $718 million, and tiered high single digit to mid-teen royalties on future net sales of any approved medicines resulting from the collaboration.

The transaction remains subject to the expiration or termination of the applicable waiting period under the HSR Act, as well as the satisfaction of other customary closing conditions and, where applicable, receipt of other required regulatory approvals.

Zymeworks will conduct the Phase 1a monotherapy trial of ZW209 in collaboration with Roche, bringing together Zymeworks' expertise in multispecific antibody therapeutics with Roche's global capabilities in the research, development, manufacturing and commercialization of cancer medicines. Roche will fund the Phase 1a trial and be responsible for subsequent global development and commercialization of ZW209. Under the agreement, Roche will have the exclusive right to develop and commercialize ZW209 globally.

"This collaboration allows us to continue advancing ZW209 through its initial clinical development while leveraging Roche's complementary capabilities to accelerate and expand its development across indications and treatment settings. The agreement also reflects our broader strategy of generating innovative programs through our R&D engine and partnering selected assets in ways that share development risk while preserving meaningful participation in their future success," said Adam Schayowitz, Ph.D., MBA, Executive Vice President and Head of R&D at Zymeworks.

"ZW209 represents an innovative approach that complements our ongoing efforts to develop new treatment options for people living with lung cancer," said Boris L. Zaitra, Head of Corporate Business Development at Roche. "We look forward to collaborating with Zymeworks to fully explore its therapeutic potential."

The collaboration is part of Zymeworks' broader strategic initiative to advance differentiated therapeutic candidates internally while selectively partnering programs where complementary capabilities can accelerate development, expand potential and share development risk. Beyond ZW209, Zymeworks has an extensive portfolio of research programs of multispecific T cell engagers against targets in solid tumors, hematological tumors, and AIID.

Investor Call Details

Zymeworks invites investors and the general public to view and listen to a live webcast of its conference call with investment analysts at 8:30 am ET on October 27, 2026.

Dial-in details and webcast link are available on Zymeworks' website at https://ir.zymeworks.com/events-and-presentations. A webcast replay of the call will be available on the Zymeworks website within 24 hours following the conclusion of the live call and will be archived for a limited period.

About ZW209

ZW209 is a novel trispecific T cell engager (TriTCE), developed to target DLL3-expressing tumor cells while simultaneously engaging T cells via binding to CD3 and CD28. Optimally configured using Zymeworks' novel TriTCE Co-Stim and clinically validated Azymetric and EFECT platforms, ZW209 is designed to enhance patient anti-tumor T cell responses through CD28 co-stimulation.

By leveraging obligate cis-T cell binding and conditional CD28 engagement, ZW209 is structured to prevent unintended T cell activation, while enabling tumor-targeted cytotoxicity. Preclinically ZW209 has demonstrated differentiated long-term cytotoxicity in vitro, with enhanced T cell proliferation and survival, offering significant potential to increase durability of responses in DLL3-expressing cancers.

With U.S. Food and Drug Administration Investigational New Drug clearance received, a Phase 1, open-label, multicenter, global study investigating ZW209 has been initiated to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity. The study will enroll adult participants with select advanced solid tumors, including small cell lung cancer and other DLL3 expressing neuroendocrine tumors.

About Zymeworks Inc.

Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. The Company's asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI? (revefenacin), with a differentiated internal research and development engine. Zymeworks' portfolio also includes Ziihera? (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks' proprietary antibody engineering technologies.

Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric? platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks' integrated drug development expertise, enable the Company to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships.

For more information about Zymeworks, its portfolio and pipeline, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks' expectations regarding implementation of its long-term strategy to maximize value creation; Zymeworks' and its partners' clinical development of product candidates; potential safety profile and therapeutic effects of product candidates; the commercial potential of technology platforms and product candidates; the anticipated benefits of its collaboration agreements; and other information that is not historical information.

When used herein, words such as "plan", "believe", "expect", "may", "continue", "anticipate", "potential", "will", "on track", "progress", "preserve", "intend", "could", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.

All forward-looking statements are based upon Zymeworks' current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks' or its partners' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; uncertainties regarding the commercial success of YUPELRI and TRELEGY; Zymeworks may not achieve milestones or receive additional payments or royalties under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks' business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks' behalf; zanidatamab may not be successfully commercialized; Zymeworks' business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks' evolution of its business strategy may not deliver meaningful stockholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue-generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates; data providing early validation of our antibody drug conjugate platform and next generation pipeline programs may not be replicated in future studies; Zymeworks' assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; the inability of Zymeworks to identify and consummate a strategic acquisition; and the factors described under "Risk Factors" in Zymeworks' quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Copyright 2026 GlobeNewswire, Inc.